Improved in vitro systems for predicting drug-induced toxicity are needed in the pharmaceutical and biotechnology industries to decrease late-stage drug attrition. One unmet need is an early screen for cardiotoxicity, which accounts for about one third of safety-based withdrawn pharmaceuticals. Herein, the first published report of a high-throughput functional assay employing a monolayer of beating human induced pluripotent stem cellderived cardiomyocytes (iPSC-CMs) is described, detailing a model that accurately detects drug-induced cardiac abnormalities. Using 96-well plates with interdigitated electrode arrays that assess impedance, the rhythmic, synchronous contractions of the iPSCCMs were detected. Treatment of the iPSC-CMs with 28 different compounds with known cardiac effects resulted in compoundspecific changes in the beat rate and/or the amplitude of the impedance measurement. Changes in impedance for the compounds tested were comparable with the results from a related technology, electric field potential assessment obtained from microelectrode arrays. Using the results from the set of compounds, an index of drug-induced arrhythmias was calculated, enabling the determination of a drug's proarrhythmic potential. This system of interrogating human cardiac function in vitro opens new opportunities for predicting cardiac toxicity and studying cardiac biology.
The capability to direct the differentiation of human pluripotent stem cells (PSCs) into functional cell types of the human body affords a novel path for a wide range of scientific study, including but not limited to cell therapy, disease modeling, translational medicine, and improved toxicity testing (Csete, 2010; Kattman et al., 2011) . Human PSC-based predictive toxicity assays are promising because they may help predict and calibrate the potential safety issues of promising drug candidates early in the development process and provide insight into the mechanisms of drug-induced organ toxicity. An added benefit of PSC-based toxicity assays would be to reduce, refine, and replace the toxicologist's reliance on animal testing and increase the relevance of preclinical safety assessment because traditional safety approaches rely heavily on animal models that do not always accurately predict human drug responses (Olson et al., 2000) . Furthermore, groundbreaking work showing that human adult cells could be ''reprogrammed'' to a pluripotent state has made possible the ability to derive pluripotent cell lines from patients with specific disease phenotypes (Yoshida and Yamanaka, 2010) . Novel induced pluripotent cell-based disease models could help identify new biomarkers as well as reveal the mechanisms of pathogenesis (Takahashi et al., 2007) . Additionally, panels of human induced PSC lines with defined human allelic variations could be created retrospectively in clinical development to help identify patient subpopulations that exhibit varied or unpredicted drug responses, aiding in the optimization of clinical trial inclusion and exclusion criteria.
Drug-induced adverse cardiovascular events are the number one cause of drug withdrawal, limitation, or development termination (Lawrence et al., 2008) . Chief among these are drug-induced torsades de pointes (TdP), French for ''twisting of the points,'' a life-threatening polymorphic ventricular tachyarrhythmia. Specifically, TdP is a morphological description of an electrocardiogram (ECG) that exhibits an oscillation around the isoelectric baseline. TdP can be self-limiting or it can degenerate into ventricular fibrillation, which is incompatible with life (Lawrence et al., 2005) . The typical cause of TdP is inhibition of the inward rectifying potassium channel, hERG (human ether-a-go-gorelated gene encoded by KCNH2), resulting in a prolongation of the time between depolarization and repolarization, known as the QT interval. To assess the risk of drug-induced TdP, new drug candidates are screened for hERG inhibition utilizing noncardiac cell lines overexpressing hERG. This assessment of in vitro hERG channel inhibition is strongly recommended by the regulatory agencies for all small molecules prior to entry into clinical development (Giorgi et al., 2010) . However, hERG screening is suboptimal because not all compounds that inhibit the hERG channel result in QT prolongation or induce TdP. For example, verapamil is a potent hERG inhibitor but does not cause QT prolongation or TdP in patients and is used safely and effectively (De Ponti et al., 2002; Meyer et al., 2004) . Additionally, QT prolongation does not always lead to TdP as ranolazine and alfuzosin both cause QT prolongation but are devoid of TdP and are considered safe (Extramiana et al., 2005; Frothingham, 2001) . Furthermore, arrhythmias can be induced in humans by drugs that do not exhibit in vitro hERG inhibition or cause QT prolongation in animal models (Chan, 2009; Demiryurek and Demiryurek, 2005) . Despite these discordances and gaps in the predictive utility of hERG screening, extensive time and effort are spent during drug discovery investigating a compound's effect on hERG inhibition and QT interval prolongation as a surrogate for human TdP potential, largely due to a lack of refined alternatives (Sager, 2008) .
One technology that can be used to identify drug-induced liabilities is microelectrode arrays (MEA), which measure electrical field potential. MEAs have been successfully used to examine homogenous and electrically coupled populations of cardiac cells, revealing an ECG-like waveform (Hescheler et al., 2004) . Changes in field potential seen by MEAs have been used as a surrogate means to measure arrhythmias (Braam et al., 2010) . However, technical limitations of MEAs, including number of assayable wells, preplating procedures, and length of time in which physiologically meaningful results can be acquired have restricted the throughput, duration, and broad acceptance of the MEA system as a means to test for potential drug-induced cardiac liabilities (Braam et al., 2010; Jonsson et al., 2010) . Within the pharmaceutical and biotech industries, if cardiovascular safety is of concern after hERG inhibition studies have been conducted, the next methods for interrogating for risk of TdP prior to animal studies are low throughput, ex vivo methods such as Langendorff, Purkinje fiber, and ventricular wedge preparations (Lawrence et al., 2005) . Thus, there is a need for a higher throughput approach that goes beyond hERG-mediated QT prolongation and delves directly into the functional interplay of the multiple voltagegated ion channels used by human myocardium to coordinate normal rhythmic contractions.
The approach described herein uses a 96-well cell culture plate with interdigitated electrode sensor arrays capable of real-time monitoring of cellular behavior through rapid (12.9 ms) impedance measurements. Impedance across the electrodes provides an indirect assessment of both the number of cells in each well and the fidelity of their interaction with the dish interface (Giaever and Keese, 1993) . Published uses of impedance in cell culture employed instruments with slower sampling rates and thus are capable of only characterizing overt cellular effects such as cytotoxicity and motility (Giaever and Keese, 1993; Xi et al., 2008) . Instruments with faster sampling rate can detect the physical movement of contracting cardiomyocytes and allows for real-time, label-free assessment of the rhythmic contraction of human induced PSC-derived cardiomyocytes (iPSC-CMs).
Human iPSC-CMs exhibit molecular and functional properties of intact human heart (Braam et al., 2010; Kattman et al., 2011) . The physical movement of contracting cardiomyocytes can be continuously monitored with nondestructive highresolution sampling of impedance across the electrode surface on the bottom of the cell culture well. Twenty-eight compounds, 25 with known cardiac liabilities and 3 negative controls, were applied to the iPSC-CMs and exhibited responses in concordance with their respective clinical findings. Furthermore, these results were qualitatively similar to those obtained using MEA.
In an effort to provide useful predictions of the clinical outcome of uncharacterized molecular entities, a novel method for quantifying drug-induced proarrhythmic risk is proposed.
MATERIALS AND METHODS
Chemicals. RO5657 was synthesized by Roche (Rotstein et al., 2009 The media was changed every 2 days after plating using maintenance media (CDI).
Expression analysis. Human Heart RNA was purchased from Ambion (adult) and Clontech (adult and fetal pool). Total RNA was purified from four independent lots of CDI iCell with the RNAqueous-4PCR Kit (Ambion). A total of 0.5 lg of total RNA was reverse transcribed using the SuperScript III First Strand cDNA Synthesis Kit (Invitrogen). TaqMan probes for each gene were purchased from Applied Biosystems (CACNA1C: Hs00167681_m1*, TNNC1: Hs00268524_m1, MYL7: Hs00221909_m1*, KCNH2: Hs00918375_m1, ACTN2: Hs00153809_m1*, SCN5A:
Hs00165693_m1*, ACTC1: Hs01109515_m1*, MYH7: Hs01110632_m1*, MYL2: Hs00166405_m1*, TNNI3: Hs00165957_m1*, TNNT2: Hs00165960_m1*, MYH6: Hs00411887_m1*, and NKX2-5: Hs00231763_m1*) and examined on the Roche LightCycler 480. Data were compared with two house keeping genes PPIA (Applied Biosystems 4333763T).
Immunostaining. CDI iCells were plated on 0.1% gelatin-coated tissue culture-treated 12-well plates (Corning) or four-chamber glass slides (BD Falcon). iCells were fixed with 4% paraformaldehyde (Sigma) in PBS for 30 min at room temperature and permeabilized with a blocking solution containing 10% normal donkey serum (Millipore), 1% bovine serum albumin (BSA; Gibco), and 0.3% Triton-X-100 (Sigma) for 1 h at room temperature. Cells were incubated with anti-CACNA1S (ab2862-abcam), anti-sodium channel Nav1.5 (S0819 or S8809), anti-Nav1.5 (ab62388-abcam), anti-troponin T cardiac isoform Ab-1 (clone 13-11; Thermo Scientific), or anti-potassium channel Kv11.1 (anti-HERG; Sigma) at a 1:100 dilution in blocking solution or 1% BSA-PBS solution overnight at 4°C. Cells were washed three times with blocking solution, followed by incubation with secondary Alexa 488 goat anti-mouse or rabbit IgG or Alexa 488 donkey anti-goat IgG (Molecular Probes) at a 1:1000 dilution in blocking solution for 1 h at room temperature. Cells were mounted with SlowFade Gold antifade reagent plus DAPI (Invitrogen) for 30 min at room temperature. The slides were imaged using a 320 Ld Plan Neofluar or 340 Ld Achroplan Zeiss objective on a Zeiss Observer Z1 microscope (Carl Zeiss Inc., Thornwood, NY).
xCelligence E-Plate and MEA replating. iCells cultured in six-well plates were transferred to 0.1% gelatin-coated E-Plate at a density of 5 3 10 4 cells per well using 0.5% trypsin-EDTA (Invitrogen). For xCelligence experimentation, background impedance measurements for E-Plate containing media without cells were made at 37°C, immediately prior to plating cells. MEAs were prepared according to the manufacturer's guidelines. Briefly, microelectrodes in six-well MEA dishes were coated with 2 ll fibronectin (Sigma) diluted 1:20 282 GUO ET AL. and incubated at 37°C for 3 h. Cells were reseeded at the target density of 3 3 10 4 cells in a 2-ll delivery to microelectrodes and incubated at 37°C, 7% CO 2 , for 3 h prior to filling each well with the maintenance media. The media of EPlate and MEAs were changed every 2 days thereafter, using maintenance media warmed to 37°C. Cells were cultured for 3-7 days prior to conducting an experiment on E-Plate or MEAs.
xCelligence and MEA experimentation. Compound stocks were prepared in dimethyl sulfoxide (DMSO) or dH 2 O at 1000-fold above the highest tested concentration. Compound stocks were serially diluted in maintenance media in a separate 96-well tissue culture plate (Corning) at 23 target concentration. The dilution plate was equilibrated to 37°C and diluted 1:1 into the E-Plate. All compounds were tested as n ! 3 on multiple E-Plates. The impedance was monitored every hour by a 20-s sweep duration by the xCelligence RTCA Cardio instrument at its maximum sampling rate (77 Hz). Data were reported as the cell index, defined as (Z i 3 Z 0 )/15, where Z i is the impedance at an individual point in time and Z 0 the background impedance.
For MEA experimentation, compound stocks were serially diluted in maintenance media to 203 the target concentrations. MEAs were equilibrated for 15 min within the MEA recorder system, prior to compound exposure. The MEA atmosphere was maintained at 37°C, 95% O 2 , and 5% CO 2 during recordings. Compound additions were made in serially increasing additions, recording for 15 min at each concentration. All compounds were tested as n ! 4 wells. Each six-well MEA possessed at least one well as the time-matched vehicle (DMSO or dH 2 O) control.
Data analysis. Data were first analyzed using the built-in analysis modules of xCelligence RTCA Cardio Software and MEAs systems. Initial results were then exported into in-house-developed Microsoft Excel templates for further semiautomated analysis. To assess the treatment-related changes in beat rate and amplitude, the measurement after treatment was normalized to the baseline (pre-drug) level and compared with that obtained from the time-matched vehicle control group. Data were expressed as the mean ± SEM, and the statistical significance of the differences was analyzed using a two-sample Student's t-test (Excel 2003 SP3), assuming equal variances, with a p value < 0.05.
To calculate the predicted proarrhythmic score (PPS), we first determined an irregular beat ratio (IBR). The IBR was defined as the ratio of arrhythmic beat counts to the total number of beats over 1 min (see Supplementary Fig. 1 for an example). Arrhythmic contractions/beats were defined in both xCelligence and MEA recordings as those with largely reduced amplitude and occurred prematurely prior to an anticipated regular contraction/beat. IBR values for each concentration at each selected time point were averaged from each replicate. The lowest concentration of drug that generated an IBR value !0.2 was determined and termed IB 20 . Finally, the maximal clinical drug exposure achieved in plasma after dosing (C eff ) obtained from literature (Supplementary Table 1 ) was divided by the IB 20 to arrive at the PPS.
RESULTS

Molecular Characterization of the Human iPSC-CMs
All experiments were conducted with synchronously beating, confluent, nondividing monolayers of iPSC-CMs. The cells, extensively characterized elsewhere, are greater than 90% cardiomyocytes containing a mix of atrial, nodal, and ventricular subtypes (Csete, 2010; Kattman et al., 2011) . To confirm the cardiac nature of the iPSC-CMs, the expression of major cardiac contractile proteins was examined (Fig. 1) . RNA was prepared from four different lots of iPSC-CMs and compared with human heart samples (two adult and one fetal). Samples from iPSC-CMs were compared with fetal tissue, as PSC-derived cardiomyocytes more closely resembled the fetal heart (Cao et al., 2008; Xu et al., 2009) . The cardiac-specific myosin light and heavy chains (MYL2, MYL7, MYH6, and MYH7), cardiac troponins (TNNI3, TNNT2, and TNNC1), ion channels (SCN5A, CACNA1C, and KCNH2), and two actinrelated genes (ACTN2 and ACTC1) were examined (Fig. 1a) . As expected, the expression of MYL2, MYH7, TNNI3, SCN5A, and KCNH2 more closely resembled the fetal expression than the adult did. In contrast, MYH6 expression is more closely related to the adult levels than fetal, whereas MYL7, MYH7, and TNNI3 expression levels are lower than either fetal or adult.
In addition, iPSC-CMs stained positive for cardiac troponin T, appearing as punctate fibrous striations across the length of the cells, which is a hallmark of functional myocytes (Fig. 1b) . Expression of a-actinin appeared homogenously throughout the cell as fibrous strands, whereas a/b-myosin heavy chain was both globular and punctate striations. The protein expression of Na þ , L-type Ca 2þ , and hERG channels was observed predominantly at the intermembrane surfaces (Fig. 1b) . The presence of these channels, which are primarily responsible for action potential depolarization and repolarization, confirm that these cells have the expected complement of properties expected in a functional cardiomyocyte.
Functional Properties of the Human iPSC-CMs as Detected by High-Resolution Impedance Measurements
Multiple lots of cells were examined by high-frequency impedance measurements and by MEA. After a period of approximately 3-4 days after plating, the monolayers of iPSCCMs exhibited a regular, oscillating impedance values indicative of rhythmic beating (Fig. 2a) . The oscillation or ''beat rate'' of untreated iPSC-CMs averaged approximately 40 beats/min across individual wells, plates, cell lots, and experiments. This observed beat rate was consistent with the beat rate detected using MEA in parallel experiments (Fig. 2b) . To confirm the hypotheses that the synchronous oscillations of impedance over time are attributed to the physical movement of the iPSC-CMs during contraction and that impendence changes are distinct from the electrical membrane potential, a tool molecule (blebbistatin) capable of binding to myosin II and preventing contraction was examined (Fig. 2b, Supplementary Video 1) . Following treatment of iPSC-CMs with blebbistatin, the cells were no longer visibly contracting and the impedance-detected beating was absent; yet, the action potential detected by MEA remained unchanged. This result with blebbistatin demonstrates that impedance measurements reflect the physical movement of the confluent monolayer of iPSC-CMs and that impedance is a property that is distinct from electrical field potential.
Using impedance measurements, the effects of different classes of known cardioactive compounds on iPSC-CMs were characterized (Figs. 2b and 2c, Supplementary Table 1) . Treatment of iPSCCMs with either tetrodotoxin, a Na þ channel blocker isolated from DRUG-INDUCED PROARRHYTHMIA IN CARDIOMYOCYTES 283 puffer fish toxin, or ZD7288, a blocker of pacemaker currents (I f ), reduced the beat rate as expected (Baruscotti et al., 2005; Ju et al., 1996) . Isoproterenol, a b-adrenergic receptor agonist, increased both beat rate and amplitude. Ouabain, a positive inotropic agent that blocks the Na þ /K þ -ATPase and elevates intracellular Na þ and Ca 2þ , increased beat amplitude. Treatment with nifedipine, a blocker of L-type Ca 2þ channel, decreased the beat amplitude and increased beat rate. The alterations in cardiac function seen using impedance with these cardioactive compounds were similar to the results obtained using MEA (Figs. 2b and 2c) . As a negative control, compounds that do not directly alter cardiomyocyte function in vivo such as aspirin (Fig. 3a) , amoxicillin, and captopril ( Supplementary Fig. 2 ) did not affect beat patterns in human iPSCCMs. These results accurately reflected the anticipated outcomes based on the current molecular knowledge and in vivo effects associated with the suite of compounds tested. The results with MEA and impedance measurements demonstrate that both approaches can detect the expected responses of known modulators of cardiac ion channels and that the channels necessary to enable human cardiomyocyte beating are functional and responsive in human iPSC-CMs.
The potential to induce and detect proarrhythmic signals in human iPSC-CMs was also assessed. The potent hERG channel inhibitor, E-4031 induced a dose-dependent reduction in beat rate but also induced instances of erratic impedance changes reminiscent of arrhythmic muscle fibrillations resulting from delayed repolarizations (Fig. 3b, Supplementary Fig. 3 , Supplementary Video 2). Given the important role alterations Ca 2þ levels can play in the onset of arrhythmia, it was hypothesized that the E-4031-induced erratic impedance changes were reflective of a physiologically meaningful arrhythmia and the modulation of Ca 2þ trafficking would rescue E-4031-induced irregularities (Clusin, 2003) . To test this hypothesis, nifedipine treatment following the onset of E-4031-induced irregularities was conducted and was able to restore the regular beat rhythm, as observed with both MEA and impedance (Fig.  3b) . This result supports our notion that impedance measures an ion channel-dependent, drug-induced arrhythmia, which can be resolved using a clinically relevant tactic, Ca 2þ channel antagonism. To confirm, a similar ''rescue'' experiment was conducted with RO5657, an internal late-stage compound that was terminated from development due to TdP in nonhuman primates (Misner et al., unpublished data) . RO5657 treatment resulted in a dose-and time-dependent onset of arrhythmic impedance traces in human iPSC-CMs (Fig. 3b, Supplementary  Fig. 4 ). Similar to E-4031, RO5657-induced irregularities were reversed to a baseline state following nifedipine treatment (Fig. 3b) .
To expand on the analysis, a diverse panel of compounds clinically associated with drug-induced arrhythmia was examined. Compounds with hERG, QT interval prolongation, and TdP liability, including astemizole, cisapride, dofetilide, erythromycin, flecainide, quinidine, sotalol, terfenadine, and thioridazine (Redfern et al., 2003) , all induced a dose-and time-dependent irregular beating pattern (Fig. 3a, Supplementary Table 1) . The drug-induced arrhythmic impedance traces were reminiscent of TdP-type arrhythmias, consisting of short runs of small, fast, asynchronous oscillations interrupting the full relaxation state between the normal rhythmic contractions whose rate was markedly reduced (Fig. 3a, Supplementary Figs. 2-6 ). In contrast, the arrhythmic beats caused by ouabain and aconitine, compounds that induce non-TdP arrhythmia in the absence of hERG inhibition or QT prolongation, were characterized by fibrillation-like arrhythmic fasciculations (Fig. 3a, Supplementary video 3) .
Impedance measurements were collected from iPSC-CMs treated with ranolazine, alfuzosin, verapamil, and moxifloxacin, all compounds that inhibit hERG and/or prolong the QT interval yet do not clinically induce TdP (Bhandari and Subramanian, 2007; Extramiana et al., 2005; Redfern et al., 2003) . At concentrations substantially higher than used clinically, ranolazine ( Supplementary Fig. 7 ) and alfuzosin (Fig. 3a) reduced the beat rate and led to arrhythmia, similar to other hERG channel blockers. It is only at these high concentrations that these drugs disproportionately inhibit multiple cardiac ion channels in a manner that results in the loss of ionic homeostasis and favors the initiation of arrhythmia (Lacerda et al., 2008; Singh and Wadhani, 2004 ). Arrhythmias were not observed following treatment with verapamil ( Supplementary Fig. 8 ) or moxifloxacin (not shown) at any of the concentrations tested. Terfenadine, a drug withdrawn from the market due to unacceptable risk of TdP, blocks multiple cardiac ion channels (hERG, Na þ , and Ca 2þ ) (Ming and Nordin, 1995; Roy et al., 1996) and induced arrhythmia only after extended treatment (!12 h) ( Supplementary Fig. 5 ). These findings demonstrate that this system using iPSC-CMs and impedance detection can distinguish compounds that inhibit hERG, or prolong the QT interval, yet do not clinically induce TdP and highlight the importance of dose and duration of drug exposure when assessing drug safety.
In an attempt to translate these findings into a process with added utility for drug discovery, a quantitative system for ranking new drug candidates by their predicted risk of causing cardiac arrhythmias was devised (Table 1 , ''Materials and Methods'' section). First, the lowest concentration of each test compound that first resulted in greater than 20% irregular beats (IB 20 ) over 1 min from the traces collected over a 72-h time course was identified ( Supplementary Fig. 1) . Next, the clinical efficacious concentration (C eff ; Supplementary Table 1) for the respective test compound was divided by the IB 20 . Thus, this metric, called the ''predicted proarrhythmic score,'' attempts to quantify a drug's impedance-detected arrhythmias relative to its efficacious exposure.
Based on an examination of the results data with respect to clinical TdP incidence, a threshold for the PPS of 100 was empirically chosen for risk of arrhythmogenesis. This value represents a 10-fold or less difference in an arrhythmia-inducing concentration relative to a drug's efficacious concentration. Cardioactive compounds like ouabain, aconitine, quinidine, dofetilide, flecainide, erythromycin, and terfenadine induce arrhythmia at concentrations less than or equal to the efficacious concentration and yield a PPS above 100 (Table 1 ). All the other compounds with a high PPS are associated with clinical observations of TdP and/or induced arrhythmia at concentrations within fivefold of efficacious exposure. Compounds with little or no observed effects on inducing arrhythmia had a low PPS (< 100), which included compounds with very low risk of TdP (moxifloxacin and amiodarone), compounds that prolong QT duration yet do not clinically induce TdP (alfuzosin and ranolazine), and compounds devoid of QT prolongation and TdP liability (amoxicillin, aspirin, captopril, nifedipine, rofecoxib, and verapamil) (Poluzzi et al., 2010; Redfern et al., 2003; Sager, 2008) . The determination of PPS using iPSC-CMs demonstrates an improvement in accuracy of predicting cardiac arrhythmias compared with hERG screening. For example, ranolazine and verapamil inhibit hERG, and alfuzosin and ranolazine induce QT prolongation yet are not torsadogenic in our model or in humans. Thus, quantifying proarrhythmic risk by calculating PPS may be useful for providing additional context to hERG inhibition results and may prospectively predict the clinical outcome of uncharacterized molecular entities.
DISCUSSION
The use of human stem cell-derived tissues as a means to better predict safety has been a long sought after goal (Davila et al., 2004) . However, to date one major hurdle researchers faced was the reproducible production of sufficient quantities of well-defined differentiated cells. In addition, new technologies capable of providing quantifiable data about the functionality of the cells and its relevance to exposed individuals are required (Hescheler et al., 2004) . Our study is one of the first efforts that attempts to bridge these gaps through technologies that interrogate distinct functional aspects of human iPSC-CMs and describes a novel method for calculating a metric of arrhythmic risk.
Like many PSC-derived tissues, gene expression analysis indicated that these cells resemble the fetal tissues more so than the adult. An open question about the utility of PSC-derived tissues in safety has been whether their fetal-like nature would impede the ability to identify adverse outcomes observed in adult patients. Thus, the hypothesis tested was that the fetallike iPSC-CMs respond to drug treatment in a manner similar to that seen clinically. Importantly, drug-induced arrhythmias were detected with human iPSC-CMs suggesting these cells have all the necessary components to analyze clinically relevant adult outcomes.
The ability to collect continuous nondestructive impedance measurements over a period of days is a particularly valuable tool to assess the functionality of human iPSC-CMs and has the potential to uncover previously unappreciated safety aspects for a given molecule. For example, delayed arrhythmic responses induced by drugs such as terfenadine and thioridazine are often missed in in vitro experiments of shorter duration (Lawrence et al., 2006; Martin et al., 2004; Masumiya et al., 2004; Peng et al., 2010) . The delayed responses with the multichannel blockers terfenadine and thioridazine suggest time-dependent affinities for different ion channels (Crumb et al., 2006; Mousavizadeh et al., 2002) . From a mechanistic perspective, the hERG-inhibiting properties of terfenadine contribute to the drug's torsadogenic liability, but it may be feasible the shortterm electrophysiological effects are masked by the drug's Ca 2þ and Na þ channel inhibition (Hove-Madsen et al., 2006) . Thus, real-time continuous analysis of beat rate and arrhythmogenicity in iPSC-CMs may be a meaningful way to shed insight into the pleiotrophic mechanisms causing adverse cardiovascular events in humans.
Drug-induced disruption of the regular iPSC-CM beat rate was translated into a quantitative measure of a PPS that accurately separated the tested compounds known to be safe and those with known contraindications in the clinic. Nevertheless, opportunities remain for refinement of this model. No attempt was made to account for the free drug concentration in the serum-containing culture media. Furthermore, refined analysis software will be needed to achieve the optimal high-throughput potential of this model. Future automated, statistically robust software capable of analyzing beat waveforms, beat duration, amplitude, and beat-to-beat intervals would enable a deeper and rapid exploration of the biology underlying the interplay of the many cardiac ion channels that regulate cardiomyocyte function. 
Note. The concentration that causes the incidence of 20% or more arrhythmic beats out of total beats over 1 min (IB 20 ) is identified for each compound. The PPS is calculated by dividing the effective therapeutic plasma concentration (C eff , in nM) by the IB 20 (in lM). A PPS greater than 100 (as a level of concern) was selected as the threshold that separates known arrhythmogenic compounds from those considered safe or with low proarrhythmic risk. Data on hERG inhibition, QT prolongation, and TdP are compiled from the literature. (þ) and (À) represent positive or negative signal, whereas as (±) means equivocal results are reported. Compounds in categories 1-3 from Redfern et al. (2003) are denoted by (þ) for TdP, except for amiodarone, which is considered a safe drug by some clinicians (Sager, 2008) . (À) for TdP represents no or two or less cases reported in the literature. * indicates non-TdP type arrhythmia.
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In addition, because early development compounds would not have a thorough knowledge of clinically efficacious exposure, the PPS approach should be further optimized using data typically available at the earliest stages of drug development such as target binding assays, cell-based efficacy models, or early in vivo pharmacology models. Nonetheless, the current model provides a means to understand a drug potential to induce arrhythmia. Although the findings presented focus on establishing the biological relevance of the drug-induced changes in impedance of iPSC-CMs with the goal of improving preclinical cardiac safety assessment, the interrogation of iPSC-CMs with impedance also opens new opportunities for translational research in human cardiac cell biology, cell signaling, and disease pathogenesis.
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